http://rdf.ncbi.nlm.nih.gov/pubchem/reference/13473088

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage e335
issn 2044-5385
issueIdentifier 8
pageRange e335-e335
publicationName Blood Cancer Journal
startingPage e335
bibliographicCitation Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015 Aug 07;5():e335. PMID: 26252788; PMCID: PMC4558588.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40eaef96b433c58c7870a9b26f432351
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f87222791581c478d6d7a3a2e75a9db0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77c41995f1925b1ba59f982e6e42aa07
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c78d38086e60efee3456d4186f539e3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89b28b923b79739922fa94300f422f3a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a86edd1baca11d1491603c63431e00cc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39df510133e621e50386ba9bec6742dd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83003a06ecddcb00b42750df93639170
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_560160cd12c7e35587da9f5468ce1079
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfeb468b0af5651028794f69fdd32003
date 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1038/bcj.2015.63
https://pubmed.ncbi.nlm.nih.gov/26252788
https://pubmed.ncbi.nlm.nih.gov/PMC4558588
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39546
https://portal.issn.org/resource/ISSN/2044-5385
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
discusses http://id.nlm.nih.gov/mesh/M0203030
http://id.nlm.nih.gov/mesh/M0473784
http://id.nlm.nih.gov/mesh/M0020790
http://id.nlm.nih.gov/mesh/M0024747
http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M000599365
http://id.nlm.nih.gov/mesh/M0018277
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9633
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16722836
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_132a8504e7423e57e5565c4615cd0cd2
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9975
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_54e32599939667ce8030f6c1725ceac0
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11133

Total number of triples: 49.